64
V. Opletalová et al. / Journal of Molecular Graphics and Modelling 39 (2013) 61–64
[22] V. Opletalova, M. Pour, J. Kunes, V. Buchta, L. Silva, K. Kralova, D. Meltrova,
References
M. Peterka, M. Poslednikova, Synthesis and biological evaluation of (E)-3-
(nitrophenyl)-1-(pyrazin-2-yl)prop-2-en-1-ones, Collection of Czechoslovak
Chemical Communications 71 (2006) 44–58.
[1] J. Koenig, Does process excellence handcuff drug development? Drug Discovery
Today 16 (2011) 377–381.
[23] D. Jun, M. Chlupacova, V. Opletalova, M. Hronek, L. Opletal, Platelet antiaggre-
gating activity of 2ꢀ,5ꢀ-diazachalcones, in: F. Borelli, et al. (Eds.), Proceedings of
the 3rd International Symposium on Natural Drugs, Naples, October 2–4, 2003,
1st ed., Universita degli Studi di Napoli Federico II – Indena, Naples, Milano,
2003, pp. 255–257.
[2] T. Hou, J. Wang, Structure–ADME relationship: still a long way to go? Expert
Opinion on Drug Metabolism & Toxicology 4 (2008) 759–770.
[3] A. Bugrim, T. Nikolskaya, Y. Nikolsky, Early predictions of drug metabolism
and toxicity: system biology approach and modeling, Drug Discovery Today 9
(2004) 127–135.
[4] A.P. Li, In vitro approaches to evaluate ADMET drug properties, Current Topics
in Medicinal Chemistry 4 (2004) 701–706.
[5] S.O. Jonsdottir, F.S. Jorgensen, S. Brunak, Prediction methods and databases
within chemoinformatics: emphasis on drugs and drug candidates, Bioinfor-
matics 21 (2005) 2145–2160.
[6] H. van de Waterbeemd, Improving compound quality through in vitro and
physicochemical profiling, Chemistry & Biodiversity 6 (2009) 1760–1766.
[7] J.C. Dearden, In silico prediction of ADMET properties: how far have we come?
Expert Opinion on Drug Metabolism & Toxicology 3 (2007) 635–639.
[8] D.A. Smith, Discovery and ADMET: where are we now, Current Topics in Medic-
inal Chemistry 11 (2011) 467–481.
[9] A. Guillot, Y. Henchoz, C. Moccand, D. Guillarme, J.-L. Veuthey, P.-A. Carrupt, S.
Martel, Lipophilicity determination of highly lipophilic compounds by liquid
chromatography, Chemistry & Biodiversity 6 (2009) 1828–1836.
[10] Y. Henchoz, S. Romand, S. Rudaz, J.-L. Veuthey, P.-A. Carrupt, High throughput
log P determination by MEEK coupled with UV and MS detections, Elec-
trophoresis 31 (2010) 952–964.
[11] L. Komsta, R. Skibin´ ski, A. Berecka, A. Gumieniczek, B. Radkiewicz, M. Radon´ ,
Revisiting thin-layer chromatography as a lipophilicity determination tool – a
comparative techniques with a model solute set, Journal of Pharmaceutical and
Biomedical Analysis 53 (2010) 911–918.
[12] C. Giaginis, A. Tsantili-Kakoulidou, Alternative measures of lipophilicity: from
octanol–water partitioning to IAM retention, Journal of Pharmaceutical Sci-
ences 97 (2008) 2984–3004.
[24] SciFinder® 2011 (database online). © American Chemical Society, 2011. Avail-
[25] M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, J.J.P. Stewart, Development and use of
quantum mechanical molecular models, 76. AM1: a new general purpose quan-
tum mechanical molecular model, Journal of the American Chemical Society
107 (1985) 3902–3909.
[26] M.J.S. Dewar, K.M. Dieter, Evaluation of AM1 calculated proton affinities and
deprotonation enthalpies, Journal of the American Chemical Society 108 (1986)
8075–8086.
[27] J.J.P. Stewart, MOPAC: a semiempirical molecular orbital program, Journal of
Computer-Aided Molecular Design 4 (1990) 1–103.
[28] N. Bodor, Z. Gabanyi, C.-K. Wong,
A new method for the estimation of
partition coefficient, Journal of the American Chemical Society 111 (1989)
3783–3786.
[29] A. Gavezotti, The calculation of molecular volumes and the use of volume analy-
sis in the investigation of structured media and of solid-state organic reactivity,
Journal of the American Chemical Society 105 (1983) 5220–5225.
[30] T. Ooi, M. Oobatake, G. Nemethy, H.A. Scheraga, Accessible surface-areas
as a measure of the thermodynamic parameters of hydration of peptides,
Proceedings of the National Academy of Sciences of the United States of America
84 (1987) 3086–3090.
[31] M. Kuchar, V. Rejholec, Evaluation of lipophilicity in quantitative
structure–biological activity relations, I. Distribution coefficient, Ceskosloven-
ska Farmacie 28 (1979) 130–134 (Chemical Abstracts 92 (1980)
33481).
[32] M. Kuchar, V. Rejholec, Evaluation of lipophilicity in quantitative
structure–biological activity relations, II. Partition chromatography,
Ceskoslovenska Farmacie 28 (1979) 212–216 (Chemical Abstracts 92
(1980) 87660).
[33] M. Kuchar, V. Rejholec, E. Kraus, V. Miller, V. Rabek, Influence of intramolecular
interactions on chromatographic behaviour of arylaliphatic acids, Journal of
Chromatography A 280 (1983) 279–288.
[13] A.J. Leo, Calculating log Poct from structures, Chemical Reviews 93 (1993)
1281–1306.
[14] G. Klopman, J.-Y. Li, S. Wang, M. Dimayuga, Computer automated log P calcula-
tions based on an extended group contribution approach, Journal of Chemical
Information and Computer Science 34 (1994) 752–781.
[15] G.E. Kellogg, D.J. Abraham, Hydrophobicity: is log Po/w more than the sum of its
parts? European Journal of Medical Chemistry 35 (2000) 651–661.
[16] I.V. Tetko, V.Yu. Tanchuk, T.N. Kasheva, A.E.P. Villa, Internet software for the
calculation of the lipophilicity and aqueous solubility of chemical compounds,
Journal of Chemical Information and Computer Science 41 (2001) 246–252.
[17] S.G. Machatha, S.H. Yalkowsky, Comparison of the octanol/water partition
[34] A.J. Leo, Calculating the hydrophobicity of chlorinated-hydrocarbon solutes,
Science of the Total Environment 109 (1991) 121–130.
[35] Y. Nakagawa, K. Izumi, N. Oikawa, T. Sotomatsu, M. Shigemura, Analysis
and prediction of hydrophobicity parameters of substituted acetanilides, ben-
zamides and related aromatic compounds, Environmental Toxicology and
Chemistry 11 (1992) 901–916.
[36] O.S. Idowu, O.A. Adegoke, A. Idowu, A.A. Olaniyi, Computational models for
structure–hydrophobicity relationships of 4-carboxyl-2,6,dinitrophenyl
azo hydroxynaphtalenes, Journal of AOAC International 90 (2007)
291–298.
coefficients calculated by ClogP® ACDlogP and KowWin® to experimen-
,
tally determined values, International Journal of Pharmaceutics 294 (2005)
185–192.
[18] D. Lazewska, P. Maludzinski, E. Szymanska, K. Kiec-Konowicz, The lipophilicity
estimation of 5-arylidene derivatives of (2-thio)hydantoin with antimycobac-
terial activity, Biomedical Chromatography 21 (2007) 291–298.
[19] D.I. Batovska, I.T. Todorova, Trends in utilization of the pharmacological poten-
tial of chalcones, Current Clinical Pharmacology 5 (2010) 1–29.
[20] V. Opletalova, J. Hartl, A. Patel, K. Palat Jr., V. Buchta, Ring substituted 3-phenyl-
1-(2-pyrazinyl)-2-prop-2-en-1-ones as potential photosynthesis-inhibiting,
antifungal and antimycobacterial agents, Farmaco 57 (2002) 135–144.
[21] M. Chlupacova, V. Opletalova, J. Kunes, L. Silva, V. Buchta, L. Duskova, K. Kralova,
Synthesis and biological evaluation of some ring-substituted (E)-3-aryl-1-
pyrazin-2-ylprop-2-en-1-ones, Folia Pharmaceutica Universitatis Carolinae 33
(2005) 31–43 (Chemical Abstracts 145 (2006) 403709).
[37] P. Kastner, M. Kucharˇ, J. Klimesˇ, D. Dosedlová, Relationship between struc-
ture and reversed-phase thin-layer chromatographic lipophilicity parameters
in a group of piperazine derivatives, Journal of Chromatography A 766 (1997)
165–170.
[38] K. Takacs-Novak, P. Perjesi, J. Vamos, Determination of log P for biologically
active chalcones and cyclic chalcone analogs by RPTLC, Journal of Planar Chro-
matography 14 (2001) 42–46.
[39] Czechoslovak Pharmacopoeia, vol. 1, 4th ed., Avicenum, Praha, 1987, p. 370.